Early detection of disease
through revolutionary test-kits

We've developed a PCR-based test proven to be 1 million times more sensitive than current market standards. This breakthrough allows for cancer detection within the first year of development, shifting the paradigm from treatment to ultra-early prevention.

Investors More information

Pioneering Early Cancer Detection

When cancer is diagnosed, it is one of the worst possible pieces of news to receive. Whether it affects you, your family, or your friends, cancer has become so common that we all encounter it in some way.

At Genetic Tools, we are at the forefront of a revolutionary shift in cancer diagnostics. For twenty years, we have been developing a PCR-based testing method that is significantly more precise and sensitive than anything currently available, aiming to detect cancer at its earliest stage.

Unprecedented Precision in Diagnostics

1 in 1 Billion

Unmatched selectivity in detecting ultra-low-abundance mutations, enabling detection of a single mutant DNA copy.

10⁶ More Sensitive

Our PAP-based technology exceeds conventional PCR detection limits by a factor of one million.

Seamless Integration

Fully compatible with common laboratory equipment, working with both blood (cfDNA) and tissue (FFPE) samples.

For Professionals: A Technical Overview

Our Pyrophosphorolysis-Activated Polymerization (PAP) technology achieves unprecedented specificity and sensitivity, detecting a single mutant DNA copy in over a billion wild-type molecules (VAF < 0.1%). This method combines qPCR with thermophilic enzymes and blocked primers to eliminate false positives and push detection limits far beyond conventional PCR.

Download Technical Sheet